Navigation Links
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Date:3/2/2013

PARIS and TARRYTOWN, N.Y., March 2, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab.  Other exploratory endpoints included pharmacokinetic, biomarker, and efficacy parameters.  The efficacy data showed that treatment with four weekly subcutaneous injections of dupilumab at either 150 milligrams (mg) or 300mg per week, significantly improved the signs and symptoms of patients with moderate-to-severe atopic dermatitis (AD) whose disease was not adequately controlled with topical medications.  Specifically, patients treated with dupilumab had significant improvements in body surface area (BSA) score, Investigator Global Assessment (IGA) score, and Eczema Area Severity Index (EASI) from baseline to week 4 compared to placebo (p<0.05 vs. placebo for all measures and doses).  The significant improvements in BSA, IGA, and EASI scores were maintained at week 8 in the 300mg dose group (p<0.05 vs. placebo).  A responder analysis demonstrated that at week 4, 54.5% of patients treated with the 150mg dose and 71.4% of patients treated with the 300mg dose achieved a reduction in EASI score of 50% or greater compared to 18.8% with placebo (p<0.05).  The most common adverse events (AEs) were nasophar
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
2. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
3. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
4. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
5. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
8. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
9. Sanofi Pasteur to add 2D barcode to six more vaccines
10. Sanofi US Launches Collaborate Activate Innovation Challenge
11. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel of a ... to a recent study, which shows how grief in pregnancy ... http://photos.prnewswire.com/prnh/20140723/129709 According to US News ... more likely than others to grow up overweight or obese, ... There were two specific types of stress that caused obesity: ...
(Date:7/24/2014)... MADISON, Wis. , July 24, 2014 /PRNewswire/ ... provides specialty and compounded pharmaceuticals, announced that it ... sensitivity information unique to each individual based upon ... now possible by understanding the interaction between a ... "We,re very excited to provide this ...
(Date:7/24/2014)... 24, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... systems, today reported financial results for the first fiscal ... overview: , Revenues of $47.5 million, up 10% ... of $0.21, up 50% over last year,s comparable quarter. ... of $7.2 million, up 20% over last year,s comparable ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... ANTONIO, Feb. 28, 2011 Advanced Cell Diagnostics, ... clinical study utilizing RNAscope™ technology to detect human ... of head and neck cancer. HPV status determined ... of patient outcome and highly concordant with that ...
... 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... dividend policy for 2011 and beyond and declared that the four ... be $0.15 per share of common stock.  The $0.15 dividends will ... 15 to all stockholders who own shares of PDL on March ...
Cached Medicine Technology:ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3PDL BioPharma Announces Regular Quarterly Dividend Policy 2
(Date:7/25/2014)... Progress in understanding the molecular genetics of brain ... brain tumor treatments, according to Patrick Wen, MD, professor ... for Neuro-Oncology, Dana-Farber Cancer Institute. , At the American ... in Chicago, July 25-26, Dr. Wen will moderate a ... the development of new treatments and advancing strategies to ...
(Date:7/25/2014)... San Jose, CA (PRWEB) July 25, 2014 ... MaaS360 WorkPlace Partner Program . Splashtop Business and ... MaaS360 Market, and will leverage the MaaS360 WorkPlace ... corporate data. , Splashtop Business and Splashtop Enterprise offer ... using any device. High performance, ease of ...
(Date:7/25/2014)... July 25, 2014 Garth Brooks Chicago ... the Allstate Arena in Rosemont. Garth Brooks was one of ... released his first single in 1989. Since "Much Too Young (To ... the shows from the Tulsa, Okl. native and in the years ... see him back on a stage and in the recording studio. ...
(Date:7/25/2014)... be treated more quickly after Manchester research , ... blood test on arrival, is effective in reducing ... study shows., The findings of a research group ... could potentially make a huge difference to a ... most common reason for emergency hospital admission. In ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Ross A. ... has been invited to join the exclusive Obagi Clinical ... leading facial plastic surgeons, plastic surgeons and dermatologists. ... this exclusive Advisory Board of thought leaders held its ... the meeting was to give Obagi the opportunity to ...
Breaking Medicine News(10 mins):Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2
... $1.1 million grant to a team of scientists at the ... technology for studying the link between human health and disease ... body. The grant is one of 14 awarded nationwide ... the Human Microbiome Project. The human microbiome consists of beneficial ...
... HealthDay Reporter , TUESDAY, Sept. 14 (HealthDay News) -- ... accurate decisions in all aspects of life, new findings suggest. ... the journal Current Biology theorize that action games ... drawn from their senses in decision-making, a skill known as ...
... , TUESDAY, Sept. 14 (HealthDay News) -- Nearly half ... payments from companies that make orthopedic devices such as artificial ... articles on such devices in medical journals, a new study ... who read the articles aren,t aware of conflicts of interest ...
... Researchers at Children,s Hospital Boston have developed a ... North Carolina at Chapel Hill to engage health care ... safety and real-time pharmacovigilance. The application, "MedWatcher," allows users ... official alerts from the Food and Drug Administration (FDA), ...
... today (14 September 2010), shows that the watercress compound is ... plays a critical role in cancer development. As tumours ... send out signals which make surrounding normal tissues grow new ... nutrients. The research, led by Professor Graham Packham ...
... ROCKVILLE, Maryland, September 14, 2010 Neuralstem, Inc. ... stem cells survived in rat brains affected by ... animals showed significant improvement in some motor skill ... of Adherent Human Neural Stem Cells To Reverse ...
Cached Medicine News:Health News:New research technology to target human gut bacteria 2Health News:Action-Packed Video Games May Be Good for You After All 2Health News:Action-Packed Video Games May Be Good for You After All 3Health News:Medical Study Authors Often Fail to Disclose Industry Ties 2Health News:New iPhone app, 'MedWatcher,' to support real-time drug safety surveillance 2Health News:Watercress may 'turn off' breast cancer signal 2Health News:Neuralstem stem cells survive and differentiate into neurons in rats with stroke 2
... SureStep™ Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
AccuSign® DOA Series Opiates Test...
... The SureStep™ Drug Screen Tests are available ... for MDMA (Ecstasy). Designed using Microgenics Antibody ... the only point of care immunoassay targeted ... for both MDA and MDEA but no ...
The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
Medicine Products: